• Upcoming Events

  • New Members

  • New therapy expected to reduce COVID hospitalizations

    • Share:
    December 31, 2020

    EL CENTRO — El Centro Regional Medical Center is hopeful a new therapy for treating high-risk COVID-19 patients will limit the number of hospital admissions, improve patient outcomes and reduce strain on the hospital’s resources.

    The U.S. Department of Health and Human Services opened a temporary infusion center on the south side of the hospital Wednesday to begin administering monoclonal antibody therapeutic treatments.

    The center is the first in a pilot program to treat certain COVID-19 patients in order to prevent hospitalization and the severity of illness.

    Monoclonal antibodies are antibodies created in a laboratory. They act similarly to natural antibodies to limit the amount of virus in the body.

    The infusion center will treat patients who have tested positive for COVID-19 and are at high risk of severe illness or hospitalization. Patients at the infusion center will receive one of two monoclonal antibody therapeutics authorized by the U.S. Food and Drug Administration, either one from Eli Lilly and Co. that uses the monoclonal antibody bamlanivimab or one from Regeneron that combines the two monoclonal antibodies casirivimab and imdevimab.

    “Like many hospitals across the country, El Centro Regional Medical Center is caring for an extremely high number of patients who have developed severe cases of COVID-19,” said Assistant Secretary for Preparedness and Response Dr. Robert Kadlec. “At this infusion center, a federal medical team will be on hand to provide therapeutic treatments that can keep people from becoming so sick that they need to be hospitalized, which will help reduce the stress on the hospital, particularly the ICU, and help save lives.”

    “In our fight against COVID, adding a tool in our toolbox we call therapies to include the infusion center is going to be a win-win for this community,” said Chief Executive Officer of El Centro Regional Medical Center Dr. Adolphe Edward. “We are finally going to be able to actually treat patients at an early stage that might have had COVID and now we can actually see that besides vaccines and therapeutics we are going to win this battle.”

    The clinic will be open from 9 a.m. to 7 p.m. and can accommodate 28 to 30 patients per day.

    The medicines are administered through an intravenous infusion treatment. The infusion of the therapeutic and medical observation together take approximately 2.5 hours. ECRMC patients who meet the criteria will be treated with the therapeutic by a team of medical professionals from the National Disaster Medical System (NDMS).

    Both products can be used to treat adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) who have positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. High risk adults meet at least one of the following criteria:

    • Have a body mass index (BMI) of 35 or greater;
    • Have chronic kidney disease;
    • Have diabetes;
    • Have immunosuppressive disease;
    • Are currently receiving immunosuppressive treatment;
    • Are 65 years of age or older.

    FDA defines high-risk differently for children; that definition is available on the FDA website.

    Patients who test positive for COVID-19 and meet the criteria can be referred by their medical provider to receive the infusion treatment. In El Centro patients who have a positive COVID-19 test and are referred by their doctor or who receive a positive COVID-19 test in the El Centro Regional Medical Center emergency room can be referred to the infusion center to receive the treatment within 10 days of testing positive.

    Monoclonal antibody treatments have been shown to decrease hospitalization rates in people at highest risk for severe disease from COVID-19. This therapy requires an infusion within the first 10 days after diagnosis, which may require healthcare systems to create new clinical pathways to administer the medicine to patients at the highest risk of developing severe cases of COVID-19.

    In November, the FDA issued emergency use authorizations to permit the emergency use of two monoclonal antibody therapeutics to treat mild to moderate COVID-19 in non-hospitalized patients: bamlanivimab from Eli Lilly and Co. was authorized for emergency use on Nov. 9, and Regeneron’s therapeutic was authorized on Nov. 21.

    Working with the Department of Defense, HHS is partnering with multiple companies to develop, manufacture, and make available therapies to treat COVID-19.

    To learn more about the monoclonal antibody therapeutic treatments ASPR has purchased and currently is allocating nationwide, visit phe.gov.